Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Source: View publication →
In patients with advanced clear cell renal cell carcinoma progressing after prior anti-PD-1/L1 therapy, the combination of the HIF-2α inhibitor belzutifan and the VEGFR-TKI lenvatinib significantly improved progression-free survival and objective response rate compared to cabozantinib alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
LITESPARK-011 represents a pivotal shift in the post-immunotherapy landscape for advanced clear cell RCC. By utilizing a first-in-class HIF-2α inhibitor in combination with a potent VEGFR-TKI, it provides orthogonal angiogenesis inhibition that outperforms a contemporary standard-of-care single-agent TKI (cabozantinib) in progression-free survival and response durability. This establishes belzutifan plus lenvatinib as a highly active, potential new standard regimen for patients who have progressed on front-line immune checkpoint inhibitors.
Historical Context
The treatment paradigm for advanced clear cell renal cell carcinoma underwent a dramatic shift with the advent of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors, which became standard front-line therapy, often in combination with TKIs. However, patients inevitably experience disease progression, and there has been no single globally accepted standard of care in the refractory setting. Cabozantinib, a multi-targeted TKI, was frequently utilized based on older trials designed before front-line immunotherapy became standard. Clear cell RCC is largely driven by VHL mutations leading to dysregulation of the hypoxia-inducible factor (HIF) pathway. Belzutifan is a first-in-class oral HIF-2α inhibitor previously approved for heavily pretreated patients. LITESPARK-011 was the first Phase 3 trial to successfully demonstrate that combining a HIF-2α inhibitor with a VEGFR-TKI improves clinical outcomes over a standard TKI in the post-immunotherapy setting.
Guided Discussion
High-yield insights from every perspective
Clear cell renal cell carcinoma is classically associated with the inactivation of the VHL tumor suppressor gene. Based on this pathophysiology, how does the combination of belzutifan and lenvatinib provide a dual mechanistic blockade of tumor progression compared to standard single-agent TKIs?
Key Response
Loss of VHL leads to accumulation of HIF-2alpha, which acts as a transcription factor driving VEGF production. Belzutifan directly inhibits HIF-2alpha (targeting the upstream driver), while lenvatinib inhibits the VEGF receptor (targeting the downstream mediator). This dual vertical blockade targets both the direct genetic consequence of the disease and its microenvironmental angiogenic effect.
Patients treated with the combination of belzutifan and lenvatinib have a distinct toxicity profile compared to those receiving cabozantinib. What unique, dose-limiting adverse effects must be monitored closely with belzutifan therapy, and how do they differ from classic TKI toxicities?
Key Response
Belzutifan commonly causes anemia and hypoxia due to its on-target inhibition of HIF-2alpha, which normally drives erythropoietin production and erythropoiesis. Residents must know to monitor hemoglobin and oxygen saturation in these patients, which contrasts with the typical VEGFR-TKI toxicities like hypertension or palmar-plantar erythrodysesthesia seen with lenvatinib or cabozantinib.
In the post-immunotherapy space for advanced ccRCC, cabozantinib is a standard of care partly due to its MET and AXL inhibition, which are resistance pathways to VEGF-targeted therapies. Given the PFS benefit of belzutifan plus lenvatinib in LITESPARK-011, how should prior front-line therapy regimens (e.g., pembrolizumab/lenvatinib versus ipilimumab/nivolumab) influence the choice between these second-line options?
Key Response
Fellows must navigate treatment sequencing carefully. If a patient received a VEGFR-TKI upfront (such as lenvatinib with pembrolizumab), re-challenging with lenvatinib in the second line may be less effective or yield more compounded toxicity than switching to a different TKI like cabozantinib. Conversely, after pure IO-IO therapy (ipilimumab/nivolumab), the belzutifan/lenvatinib combination might be particularly potent given the lack of prior TKI exposure.
While LITESPARK-011 demonstrated significant PFS and ORR benefits for belzutifan plus lenvatinib over cabozantinib, how does the requirement for continuous daily dual oral therapy and its compounded toxicities impact real-world shared decision-making, particularly while awaiting mature overall survival data?
Key Response
Attendings must balance statistically significant efficacy with patient quality of life and regimen complexity. Dual oral agents often require frequent dose interruptions and modifications in real-world practice, which can compromise efficacy compared to a highly controlled clinical trial setting. Waiting for mature overall survival (OS) data is essential before completely abandoning single-agent cabozantinib, which is a proven, familiar, and potentially less burdensome option for many patients.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
LITESPARK-011 is an open-label trial utilizing Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) as a primary endpoint. What are the methodological vulnerabilities of using PFS in an open-label setting with an experimental combination therapy, and how might asymmetric treatment discontinuation inflate the effect size?
Key Response
In open-label trials, investigators and patients are aware of the treatment allocation. This knowledge can influence the clinical threshold for discontinuing therapy due to toxicity or subjective clinical deterioration before radiographic progression is formally documented, leading to informative censoring. While BICR mitigates radiographic reading bias, it cannot rescue bias introduced if control arm patients drop out earlier or miss scheduled scans at a different rate than the experimental arm.
As a reviewer evaluating the LITESPARK-011 manuscript, what critical scrutiny must be applied to the dose intensity and dose modification rates of the cabozantinib control arm compared to historical norms to ensure the control arm did not artificially underperform?
Key Response
A classic threat to trial validity in superiority studies is a straw man control arm. Editors must verify whether cabozantinib patients received adequate dose intensity (typically a 60 mg starting dose) and if the discontinuation rate matched historical data from trials like METEOR. If the control arm underperformed due to strict trial protocols or poor toxicity management, the comparative benefit of the novel combination may be exaggerated.
Based on the superiority in PFS and ORR demonstrated in LITESPARK-011, should belzutifan plus lenvatinib replace single-agent cabozantinib as the preferred Category 1 recommendation for second-line therapy in ccRCC post-PD-1/L1 progression, or does the lack of mature Overall Survival (OS) data restrict this to an alternative option under current NCCN/ESMO frameworks?
Key Response
Current guidelines strongly recommend cabozantinib in this setting based on OS benefits seen in prior trials. The committee must decide if a PFS and ORR benefit alone in a phase 3 trial is sufficient to usurp a standard of care with proven OS. Typically, without an OS benefit, the new combination might receive a Category 1 or 2A recommendation as a preferred option, but cabozantinib would remain heavily endorsed until mature survival data for the combination confirm a definitive advantage.
Clinical Landscape
Noteworthy Related Trials
METEOR Trial
Tested
Cabozantinib 60 mg daily
Population
Patients with advanced RCC progressing after prior VEGFR-targeted therapy
Comparator
Everolimus 10 mg daily
Endpoint
Progression-free survival (PFS)
CLEAR Trial
Tested
Lenvatinib plus pembrolizumab or lenvatinib plus everolimus
Population
Patients with previously untreated advanced renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Progression-free survival (PFS)
LITESPARK-005 Trial
Tested
Belzutifan 120 mg daily
Population
Patients with advanced RCC progressing after immune checkpoint and antiangiogenic therapies
Comparator
Everolimus 10 mg daily
Endpoint
Progression-free survival (PFS) and Overall Survival (OS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis